

James C. Greenwood President & CEO

January 17, 2018

The Honorable Brett Guthrie 2434 Rayburn House Office Building Washington, DC 20515

Dear Representative Guthrie:

I write on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations, to express our support for H.R. 2026, the "Pharmaceutical Information Exchange Act." This legislation would provide biopharmaceutical manufacturers with additional clarity and certainty in the exchange of health care economic and other scientific information about investigational new drugs and investigational uses of approved drugs with health care decision makers such as payors and formulary committees.

On December 13, 2016, the 21st Century CURES Act was signed into law. This landmark legislation, spearheaded by the Energy and Commerce Committee, focused on bolstering the speed and efficiency in which new cures and treatments reach patients across America. One of the tenets of 21st Century CURES was to increase the flow of information between pharmaceutical manufactures and other health care decision makers so that patients can access groundbreaking biopharmaceutical innovations as quickly and effectively as possible.

BIO believes that H.R. 2026 builds on the important progress made in 21st Century CURES. As value-based health care and contracting become more and more prevalent, so does the need to ensure stakeholders are able to share timely, scientifically-based information with one another before a product comes to market. Most importantly, this bill will help ensure patients have access to the latest and greatest medical breakthroughs science has to offer.

With Sincerest Regards,

lin Corunwood

James C. Greenwood President and CEO